KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Share-based Compensation (2017 - 2025)

Twist Bioscience (TWST) has disclosed Share-based Compensation for 7 consecutive years, with $11.7 million as the latest value for Q3 2023.

  • On a quarterly basis, Share-based Compensation fell 38.33% to $11.7 million in Q3 2023 year-over-year; TTM through Sep 2023 was $30.3 million, a 61.99% decrease, with the full-year FY2025 number at $64.5 million, up 26.58% from a year prior.
  • Share-based Compensation was $11.7 million for Q3 2023 at Twist Bioscience, up from $10.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $22.5 million in Q1 2022 to a low of -$2.3 million in Q4 2022.
  • A 5-year average of $9.1 million and a median of $9.2 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 402.82% in 2019, then plummeted 112.84% in 2022.
  • Twist Bioscience's Share-based Compensation stood at $3.7 million in 2019, then skyrocketed by 89.94% to $7.0 million in 2020, then surged by 157.88% to $18.1 million in 2021, then plummeted by 112.84% to -$2.3 million in 2022, then surged by 605.25% to $11.7 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Share-based Compensation are $11.7 million (Q3 2023), $10.6 million (Q2 2023), and $10.3 million (Q1 2023).